Pharmaceutical

GSK’s Jemperli approved for advanced endometrial cancer in Singapore

GSK Singapore obtained the Singapore HSA approval for a new indication for Jemperli for advanced or recurrent endometrial cancer.

Aug 9, 2024 - 04:00
GSK’s Jemperli approved for advanced endometrial cancer in Singapore
GSK Singapore obtained the Singapore HSA approval for a new indication for Jemperli for advanced or recurrent endometrial cancer.
Read the original article

Tags:

Previous Article

Amneal’s CREXONT gains FDA approval for Parkinson’s treatment

Next Article

US FDA approves Novartis’ Fabhalta in IgAN treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Bayer applies for EU approval of menopause drug elinzanetant

Bayer applies for EU approval of menopause drug elinzan...

Oct 16, 2024

Hasten Biopharmaceutic raises $315m for pipeline assets development

Hasten Biopharmaceutic raises $315m for pipeline assets...

Apr 20, 2023

STAT+: Hospital claims it was ‘drastically’ overcharged by pharma in a federal drug discount program

STAT+: Hospital claims it was ‘drastically’ overcharged...

Feb 15, 2024